SCHEMBL12890243

SCHEMBL12890243

FC(F)(F)c1cccc(-c2csc(COC3CCCCO3)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.47
CASP3 P42574 1/20 0.44
CASP7 P55210 1/20 0.44
CASP8 Q14790 1/20 0.44
ALDH1A1 P00352 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SCN9A Q15858 2/20 0.39
UCHL1 P09936 1/20 0.39
ADAM17 P78536 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2B Q13224 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CFTR P13569 1/20 0.38
ITGB3 P05106 2/20 0.38
ITGA2B P08514 2/20 0.38
CNR2 P34972 1/20 0.38
LTA4H P09960 1/20 0.38
KDM1A O60341 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876137 0.85 ATP4A (0.39) CASP3ALDH1A1KDM4EMEN1KMT2A
SCHEMBL1198819 0.82 ALDH1A1 (0.44) ARCASP3CASP7CASP8ALDH1A1
SCHEMBL2431523 0.78 GRIN1 (0.42) GRIN1GRIN2BL3MBTL1KDM4C
SCHEMBL1199248 0.77 GRIN1 (0.38) ARALDH1A1MEN1KMT2AGRIN1
SCHEMBL1198600 0.76 GRIN1 (0.38) ARALDH1A1MEN1KMT2AGRIN1
SCHEMBL1198888 0.75 GRIN1 (0.37) ARALDH1A1MEN1KMT2AGRIN1
SCHEMBL1199541 0.75 PPARG (0.40) ALDH1A1MEN1KMT2AGRIN1GRIN2B
SCHEMBL1199130 0.75 MAPT (0.39) ARALDH1A1MEN1KMT2AGRIN1
SCHEMBL1197624 0.75 MEN1 (0.41) ALDH1A1MEN1KMT2AGRIN1GRIN2B
SCHEMBL1198026 0.72 MEN1 (0.52) ARCASP3CASP7CASP8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A AR 202/4885CASP3 2238/4885CASP7 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.